Latest Asx News

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Godolphin Resources has completed its first phase of drilling at Lewis Ponds, intersecting significant massive and semi-massive sulphide mineralisation that could underpin an upgrade to its existing resource estimate.

A1 Investments & Resources Ltd reported a modest cash outflow for Q1 2024 while actively pursuing renewable energy acquisitions in Japan and Australia, contingent on regulatory approvals and shareholder consent.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

GTi Energy has completed drilling two of three groundwater monitoring wells at its Lo Herma ISR Uranium Project, progressing critical infrastructure ahead of aquifer testing and resource development.

NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Great Divide Mining's latest LiDAR analysis at Devils Mountain reveals a wealth of previously unknown historical mine workings, significantly sharpening its gold exploration focus in southeast Queensland.

Resource Mining Corporation reports promising copper-gold exploration results at its Mpanda project in Tanzania, secures $1 million in loan funding, and gains an option to acquire a 70% stake in a Saudi Arabia joint venture.

Lodestar Minerals has raised $520,000 through a share placement to fund its inaugural reverse circulation drilling at the Darwin gold project in Chile, signaling a pivotal step in its exploration strategy.